At MabVax Therapeutics Holdings, Inc., we are advancing a pipeline of human monoclonal antibody products that are based on the protective immune responses generated by patients who have been immunized against targeted cancers with our proprietary vaccines.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our lead fully human antibody candidate HuMab 5B1 as a therapeutic treatment for metastatic pancreatic cancer.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our HuMab 5B1-based companion diagnostic product as a next-generation PET imaging agent for the diagnosis and treatment assessment of metastatic pancreatic cancer.

• We have a Phase 2-ready therapeutic cancer vaccine for the childhood cancer neuroblastoma with plans to enter the clinic in 2016. Our vaccine has been granted Orphan Drug Designation by the FDA.

• We have a robust antibody discovery platform with multiple fully developed human antibody leads to 11 targets. Our leads are developed from our exclusive license with Memorial Sloan Kettering Cancer Center.

• Members of our executive management team and board of directors all have significant experience in the development of drugs and diagnostics.

>Read More about MabVax Therapeutics


February 3rd, 2016
MabVax Therapeutics to Present at BIO CEO and Investor Conference
Read More >

February 1st, 2016
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
Read More >

January 19th, 2016
MabVax Therapeutics executes a Debt facility for up to $10 million dollars
Read More >

January 6th, 2016
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1 Enrollment in Trial with New PET Imaging Agent Expected to Begin in Early 2016
Read More >

January 4th, 2016
MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer
Read More >

To Access the Live Webcast with Illustrative Slides CLICK HERE

HuMab 5B1 Program 

Shareholder Letter 

Fact Sheet 

Corporate Presentation 

   Sign up for Email Alerts

Be the first to get breaking news 


 Shareholder Letter: 

2015 MabVax Shareholder Letter.pdf 2015 MabVax Shareholder Letter.pdf
Size : 170.929 Kb
Type : pdf

Investor Presentation: 

MabVax Investor Presentation September 2015.pdf MabVax Investor Presentation September 2015.pdf
Size : 7747.416 Kb
Type : pdf


Loading data...
MabVax Therapeutics

Contact Us: MabVax Therapeutics
 11588 Sorrento Valley Road Suite 20
San Diego, California, 92121   (858) - 259 - 9405
email: info@mabvax.com

  © 2015, MabVax Therapeutics. All Rights Reserved 
Privacy Policy     Terms of Use     Disclaimer     Sitemap